If there is such a thing as a poster child for volatility in the stock market, the biotech sector would likely take top honors.Biotech stocks are unique. While stocks in other sectors are typically valued based on their past performance and future earnings potential, the majority of biotech stocks don’t have a cent in recurring revenue. Instead, biotech stocks are […]
People have called me a “perma-bull” forever. Mish Shedlock called me a “wacko”. Zerohedge has called me insane. Nouriel Roubini has laughed in my face. My daughters still quote Don Luskin when he was on CNBC shaking his head and saying, “James, James, James…” while laughing after I said the market was going to hit new highs.
Well, the market has […]
An FDA advisory panel voted in favor of approving Regeneron (REGN – Analyst Report) and partner Sanofi’s PCSK9 inhibitor, Praluent. A few deals were also signed over the last few days by companies like Vertex (VRTX – Analyst Report), Celgene (CELG – Analyst Report) and Seattle Genetics (SGEN – Analyst Report).Recap of the Week’s Most Important Stories1. Regeneron and Sanofi […]
In early April I wrote a piece arguing that biotech stocks – using the iShares Nasdaq Biotech ETF (IBB) as a proxy – looked to be under distribution. At the time the IBB traded at approximately $340. My argument rested on negative divergences in the Shares Outstanding / Price action of the IBB, Block Money Flow trends, an increase in volatility, […]
Updated 6/10 Biotech ETFs lag overall in 1.4% rally. Materials, financials and technology lead. Large cap biotechs doing well.
Rayno portfolio winners today: ALXN, BIIB, GILD, RHHBY etc
Rapid Fire Re-Balancing of ETFs into More Speculative Names
Is the Tail Wagging the Dog?
We have published a number of reports on Life Science ETFs (2/4/15) in the past and noticed changes lately that reflect a […]
Related JUNOGene Therapy Stocks Take Beating On Bad News For CelladonCAR-T Therapy Stocks Hit Hard Following AACR DataThe Real Value In MabVax May Be Partnerships Rather Than Pipeline(Seeking Alpha)While short interest in most of the leading biotechs and emerging pharmaceuticals shrank between the March 31 and April 15 settlement dates, three stocks bucked that trend.Juno Therapeutics Inc (NASDAQ: JUNO) and […]
The mixed close Tuesday further clouds the short-term market outlook as it suggests the correction from last week’s highs may not yet be over. A drop in the market tracking ETFs below last Friday’s lows will indicate a decline to more important support. The S&P futures are down in early trading and the heavy selling last week identifies that key […]
After an incredible run, investors are finally seeing some pain in the biotech and broader health care sector. Major biotechnology indexes were off over 4% in Wednesday trading, while the short term trend has not been favorable either.Some investors may now think that the bubble has burst for the high growth biotech sector, but there are actually still a few […]
View gallery.Biotech stocks have been breaking to new highs all over the market. Here are just a few:Esperion Therapeutics broke to a new high last week and skyrocketed Tuesday.
Ampio Pharmaceuticals bolted higher last week and touched a new high Wednesday.
Jazz Pharmaceuticals just hit a new high Wednesday as well.
The list goes on and on. Whether it is Receptos, NewLink Genetics, Biogen […]
View photo.Short interest among leading biotechs and emerging pharmaceuticals increased nearly all across the board between February 13 and February 27.Leading the trend were BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Celgene Corporation (NASDAQ: CELG) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX).Here, Benzinga takes a quick look at how the stocks have fared recently and what analysts expects from them, followed by a […]